Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)

メタデータ	言語:
	出版者: 東京女子医科大学学会
	公開日: 2024-01-12
	キーワード (Ja):
	キーワード (En):
	作成者: BABAZONO, Tetsuya, MURATA, Hidekazu, SATO, Manaka, TAKEUCHI, Masakazu
	メールアドレス:
	所属:
URL	http://hdl.handle.net/10470/0002000052

Supplementary Table 3. Glycated hemoglobin (%) over 12 months after adding a glucagon-like peptide-1 receptor agonist to a sodium-glucose cotransporter 2 inhibitor.

Time		All (n = 80)	DPP-4i use subgroup		BMI subgroup			HbA1c subgroup			Insulin use subgroup	
			Non-DPP-4i use (n = 62)	DPP-4i use (n = 18)	<25 kg/m^2 (n = 11)	25 to <30 kg/m^2 (n = 31)	≥30 kg/m^2 (n = 38)	<8% (n = 20)	8% to <10% (n = 45)	≥10% (n = 15)	Insulin users (n = 28)	Insulin non-users (n = 52)
Baseline	n	80	62	18	11	31	38	20	45	15	28	52
	Mean ± SD	8.9 ± 1.6	8.8 ± 1.8	9.3 ± 1.0	9.0 ± 2.2	8.7 ± 1.1	9.1 ± 1.8	7.3 ± 0.5	8.8 ± 0.5	11.5 ± 1.7	9.5 ± 2.1	8.6 ± 1.3
3 months	n	79	61	18	11	31	37	20	45	14	28	51
	Mean ± SD	7.9 ± 1.1	7.8 ± 1.1	8.3 ± 0.8	7.6 ± 0.9	7.7 ± 0.9	8.2 ± 1.2	6.9 ± 0.5	8.0 ± 0.7	9.1 ± 1.3	8.3 ± 1.3	7.7 ± 0.9
	P-value*	<0.001	<0.001	0.004	0.13	<0.001	0.028	0.37	<0.001	<0.001	<0.001	<0.001
6 months	n	80	62	18	11	31	38	20	45	15	28	52
	Mean ± SD	8.2 ± 1.3	8.1 ± 1.4	8.4 ± 1.1	7.9 ± 1.5	7.8 ± 1.0	8.5 ± 1.5	7.1 ± 0.9	8.2 ± 0.9	9.5 ± 1.6	8.7 ± 1.6	7.8 ± 1.1
	P-value*	0.002	0.022	0.018	0.28	0.002	0.32	0.98	0.001	0.005	0.008	<0.001
9 months	n	70	54	16	9	28	33	17	42	11	26	44
	Mean ± SD	8.1 ± 1.3	8.1 ± 1.5	8.3 ± 0.9	8.0 ± 1.6	7.8 ± 0.9	8.4 ± 1.5	7.1 ± 0.9	8.2 ± 1.0	9.6 ± 1.6	8.6 ± 1.6	7.8 ± 1.1
	P-value*	0.001	0.026	0.006	0.48	0.003	0.19	0.89	0.002	0.014	0.022	<0.001
12 months	n	70	54	16	9	28	33	15	42	13	25	45
	Mean ± SD	8.2 ± 1.4	8.1 ± 1.5	8.3 ± 0.9	7.7 ± 1.2	7.9 ± 1.1	8.5 ± 1.5	7.2 ± 1.2	8.1 ± 1.0	9.4 ± 1.6	8.5 ± 1.6	8.0 ± 1.1
	P-value*	0.003	0.045	0.006	0.21	0.018	0.26	1.0	0.001	0.004	0.001	<0.001

*P-values are compared with baseline.

BMI, body mass index; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; SD, standard deviation; SGLT2i, sodium-glucose cotransporter 2 inhibitor.